Medtronic is back in the news this week as new data suggests that one of their products, when used in high doses during spinal fusion procedures, may actually increase a patient’s risk for developing cancer.

The information, which was presented during a recent national meeting of spinal surgeons, was given to the FDA by Medtronic when the company sought approval to sell a high-strength version of an already existing bone growth product known as Infuse. However, based on the results of the study, the FDA subsequently rejected Medtronic’s high-dose product, which was called Amplify, due to concerns over the increased cancer risks.

The study’s data regarding the higher-dose formulation (Amplify) also revealed potential implications for patients who have previously received Infuse, as both products contain the same active ingredient. In response to the controversy surrounding the wide-spread use of Infuse, Medtronic issued a $2.5 million grant to Yale University for the purpose of conducting an independent review of all data associated with the efficacy and safety of Infuse.


Frank M. Eidson P.A. has been tirelessly representing the rights of Central Florida victims since 1989.

$4.2 Million

Auto Accident

$2.3 Million

Workers Comp Case

$5.65 Million

Auto Accident

Free, No Obligation Case Review.

Fill out our contact form below for your free, no obligation case review.

  • This field is for validation purposes and should be left unchanged.

Help provide wounded servicemen and women with therapeutic outdoor adventures. Like our Facebook page and we'll contribute $1 to Wounded Warriors Outdoors.

Contact Our Orlando Attorney

If you have been injured in an accident, turn to Frank M. Eidson P.A. Whether your case is a simple collision or a complicated auto wrongful death case, contact personal injury lawyer Frank Eidson today to schedule your free consultation.